Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.
Identifieur interne : 002591 ( PubMed/Corpus ); précédent : 002590; suivant : 002592Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.
Auteurs : Hongxuan He ; Yi Tang ; Ximing Qin ; Wenbo Xu ; Yifei Wang ; Xiangjun Liu ; Xingyou Liu ; Sheng Xiong ; Jiuxiang Li ; Meiying Zhang ; Mingxing DuanSource :
- DNA and cell biology [ 1044-5498 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), CD4-CD8 Ratio, Cell Proliferation, Female, Immunoglobulin G (blood), Interferon-gamma (blood), Interleukin-4 (blood), Lymphocyte Count, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Plasmids, Recombinant Proteins, SARS Virus (genetics), SARS Virus (immunology), Spike Glycoprotein, Coronavirus, T-Lymphocytes (immunology), Vaccines, DNA, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines.
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G, Interferon-gamma, Interleukin-4.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- genetics : SARS Virus.
- immunology : SARS Virus, T-Lymphocytes.
- Animals, CD4-CD8 Ratio, Cell Proliferation, Female, Lymphocyte Count, Mice, Mice, Inbred BALB C, Plasmids, Recombinant Proteins, Spike Glycoprotein, Coronavirus, Vaccines, DNA, Viral Vaccines.
Abstract
The spike (S) protein, a main surface antigen of the SARS coronavirus (SARS-CoV), is considered to be one of the most important protective antigen candidates for targets for vaccine design against the virus. In this study, a secreted recombinant expression plasmid, pVAX-S1, encoding the partial S protein with a signal peptide, was constructed and used to immunize BALB/c mice through electroporation. It was demonstrated that the eukaryotic expression vector pVAX-S1 was successfully constructed by restriction enzyme and sequence analysis. The expressed protein could be detected specifically by Western blot analysis. The serum IgG level of the vaccine group mice was significantly higher than that of the corresponding control group at day 14 after vaccination (P < 0.05). The vaccine group demonstrated significantly higher S1 protein lymphocyte proliferation index (LPI) than the control groups (P < 0.05). Furthermore, in the experimental group, a decrease in the ratio of CD4(+) to CD8(+) T-lymphocytes and an increase level of IFN-gamma in serum were observed. However, interleukin-4 (IL-4) was not detectable in two groups. These results strongly demonstrated that the pVAX-S1 plasmid could induce humoral and cellular immune responses in mice, and may be a potential candidate for a DNA vaccine against the SARS coronavirus.
DOI: 10.1089/dna.2005.24.516
PubMed: 16101350
Links to Exploration step
pubmed:16101350Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.</title><author><name sortKey="He, Hongxuan" sort="He, Hongxuan" uniqKey="He H" first="Hongxuan" last="He">Hongxuan He</name><affiliation><nlm:affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Tang, Yi" sort="Tang, Yi" uniqKey="Tang Y" first="Yi" last="Tang">Yi Tang</name></author><author><name sortKey="Qin, Ximing" sort="Qin, Ximing" uniqKey="Qin X" first="Ximing" last="Qin">Ximing Qin</name></author><author><name sortKey="Xu, Wenbo" sort="Xu, Wenbo" uniqKey="Xu W" first="Wenbo" last="Xu">Wenbo Xu</name></author><author><name sortKey="Wang, Yifei" sort="Wang, Yifei" uniqKey="Wang Y" first="Yifei" last="Wang">Yifei Wang</name></author><author><name sortKey="Liu, Xiangjun" sort="Liu, Xiangjun" uniqKey="Liu X" first="Xiangjun" last="Liu">Xiangjun Liu</name></author><author><name sortKey="Liu, Xingyou" sort="Liu, Xingyou" uniqKey="Liu X" first="Xingyou" last="Liu">Xingyou Liu</name></author><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name></author><author><name sortKey="Li, Jiuxiang" sort="Li, Jiuxiang" uniqKey="Li J" first="Jiuxiang" last="Li">Jiuxiang Li</name></author><author><name sortKey="Zhang, Meiying" sort="Zhang, Meiying" uniqKey="Zhang M" first="Meiying" last="Zhang">Meiying Zhang</name></author><author><name sortKey="Duan, Mingxing" sort="Duan, Mingxing" uniqKey="Duan M" first="Mingxing" last="Duan">Mingxing Duan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16101350</idno><idno type="pmid">16101350</idno><idno type="doi">10.1089/dna.2005.24.516</idno><idno type="wicri:Area/PubMed/Corpus">002591</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002591</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.</title><author><name sortKey="He, Hongxuan" sort="He, Hongxuan" uniqKey="He H" first="Hongxuan" last="He">Hongxuan He</name><affiliation><nlm:affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Tang, Yi" sort="Tang, Yi" uniqKey="Tang Y" first="Yi" last="Tang">Yi Tang</name></author><author><name sortKey="Qin, Ximing" sort="Qin, Ximing" uniqKey="Qin X" first="Ximing" last="Qin">Ximing Qin</name></author><author><name sortKey="Xu, Wenbo" sort="Xu, Wenbo" uniqKey="Xu W" first="Wenbo" last="Xu">Wenbo Xu</name></author><author><name sortKey="Wang, Yifei" sort="Wang, Yifei" uniqKey="Wang Y" first="Yifei" last="Wang">Yifei Wang</name></author><author><name sortKey="Liu, Xiangjun" sort="Liu, Xiangjun" uniqKey="Liu X" first="Xiangjun" last="Liu">Xiangjun Liu</name></author><author><name sortKey="Liu, Xingyou" sort="Liu, Xingyou" uniqKey="Liu X" first="Xingyou" last="Liu">Xingyou Liu</name></author><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name></author><author><name sortKey="Li, Jiuxiang" sort="Li, Jiuxiang" uniqKey="Li J" first="Jiuxiang" last="Li">Jiuxiang Li</name></author><author><name sortKey="Zhang, Meiying" sort="Zhang, Meiying" uniqKey="Zhang M" first="Meiying" last="Zhang">Meiying Zhang</name></author><author><name sortKey="Duan, Mingxing" sort="Duan, Mingxing" uniqKey="Duan M" first="Mingxing" last="Duan">Mingxing Duan</name></author></analytic><series><title level="j">DNA and cell biology</title><idno type="ISSN">1044-5498</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (blood)</term><term>CD4-CD8 Ratio</term><term>Cell Proliferation</term><term>Female</term><term>Immunoglobulin G (blood)</term><term>Interferon-gamma (blood)</term><term>Interleukin-4 (blood)</term><term>Lymphocyte Count</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Plasmids</term><term>Recombinant Proteins</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>T-Lymphocytes (immunology)</term><term>Vaccines, DNA</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CD4-CD8 Ratio</term><term>Cell Proliferation</term><term>Female</term><term>Lymphocyte Count</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Plasmids</term><term>Recombinant Proteins</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The spike (S) protein, a main surface antigen of the SARS coronavirus (SARS-CoV), is considered to be one of the most important protective antigen candidates for targets for vaccine design against the virus. In this study, a secreted recombinant expression plasmid, pVAX-S1, encoding the partial S protein with a signal peptide, was constructed and used to immunize BALB/c mice through electroporation. It was demonstrated that the eukaryotic expression vector pVAX-S1 was successfully constructed by restriction enzyme and sequence analysis. The expressed protein could be detected specifically by Western blot analysis. The serum IgG level of the vaccine group mice was significantly higher than that of the corresponding control group at day 14 after vaccination (P < 0.05). The vaccine group demonstrated significantly higher S1 protein lymphocyte proliferation index (LPI) than the control groups (P < 0.05). Furthermore, in the experimental group, a decrease in the ratio of CD4(+) to CD8(+) T-lymphocytes and an increase level of IFN-gamma in serum were observed. However, interleukin-4 (IL-4) was not detectable in two groups. These results strongly demonstrated that the pVAX-S1 plasmid could induce humoral and cellular immune responses in mice, and may be a potential candidate for a DNA vaccine against the SARS coronavirus.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16101350</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5498</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>DNA and cell biology</Title><ISOAbbreviation>DNA Cell Biol.</ISOAbbreviation></Journal><ArticleTitle>Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.</ArticleTitle><Pagination><MedlinePgn>516-20</MedlinePgn></Pagination><Abstract><AbstractText>The spike (S) protein, a main surface antigen of the SARS coronavirus (SARS-CoV), is considered to be one of the most important protective antigen candidates for targets for vaccine design against the virus. In this study, a secreted recombinant expression plasmid, pVAX-S1, encoding the partial S protein with a signal peptide, was constructed and used to immunize BALB/c mice through electroporation. It was demonstrated that the eukaryotic expression vector pVAX-S1 was successfully constructed by restriction enzyme and sequence analysis. The expressed protein could be detected specifically by Western blot analysis. The serum IgG level of the vaccine group mice was significantly higher than that of the corresponding control group at day 14 after vaccination (P < 0.05). The vaccine group demonstrated significantly higher S1 protein lymphocyte proliferation index (LPI) than the control groups (P < 0.05). Furthermore, in the experimental group, a decrease in the ratio of CD4(+) to CD8(+) T-lymphocytes and an increase level of IFN-gamma in serum were observed. However, interleukin-4 (IL-4) was not detectable in two groups. These results strongly demonstrated that the pVAX-S1 plasmid could induce humoral and cellular immune responses in mice, and may be a potential candidate for a DNA vaccine against the SARS coronavirus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Hongxuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Biomembrane and Membrane Biotechnology, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ximing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiangjun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xingyou</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sheng</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiuxiang</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Meiying</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Mingxing</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>DNA Cell Biol</MedlineTA><NlmUniqueID>9004522</NlmUniqueID><ISSNLinking>1044-5498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016516" MajorTopicYN="N">CD4-CD8 Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="Y">Vaccines, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16101350</ArticleId><ArticleId IdType="doi">10.1089/dna.2005.24.516</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002591 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002591 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16101350
|texte= Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16101350" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |